BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Bai R, Li W, Cui J. Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. Cancer Biol Med 2022;19:1649-61. [PMID: 36245210 DOI: 10.20892/j.issn.2095-3941.2022.0489] [Reference Citation Analysis]
2 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Hong CM, Jeong YJ, Kim HW, Ahn BC. KSNM60 in Nuclear Endocrinology: from the Beginning to the Future. Nucl Med Mol Imaging 2022;56:17-28. [PMID: 35186157 DOI: 10.1007/s13139-021-00728-0] [Reference Citation Analysis]
4 Jeong H, Shin J, Jeong JH, Kim KP, Hong SM, Kim YI, Ryu JS, Ryoo BY, Yoo C. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open 2021;6:100119. [PMID: 33901869 DOI: 10.1016/j.esmoop.2021.100119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]